Brief: Allarity Therapeutics Receives Nasdaq Notification Of Non-Compliance With Listing Rule 5250(C)(1)
26/08/2022 21:31
Aug 26 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS RECEIVES NASDAQ NOTIFICATION OF
NON-COMPLIANCE WITH LISTING RULE 5250(C)(1)
Source text for Eikon: ID:nGNX6fjS7m
Further company coverage: ALLR.O
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic